Gene therapy for ovarian cancer fails PhIII study — sinking VBL Therapeutics' shares

Despite promising interim results, VBL Therapeutics’ ovarian cancer drug has ultimately flopped in a Phase III trial.

The Nasdaq-listed Israeli biotech revealed that the OVAL trial of ofranergene obadenovec (also known as ofra-vec, or VB-111) did not meet the primary endpoints of improving upon progression-free survival or overall survival.